ClinicalTrials.gg
Enrolling by invitationNCT07196566OAF-DLCUpdated Sep 29, 2025

Double-Layer Closure Technique Using Buccal and Palatal Flaps for Oroantral Fistula

An interventional study of Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft in Oroantral Fistula and Double Layer, sponsored by Tanta University. Enrolling by invitation at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Sex
All
01

Study summary

A prospective clinical case series was conducted involving twelve patients with oroantral fistulas ≥5 mm in diameter. Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft rotated to cove the bony defect and sutured to the buccal periosteum as the first layer, then the buccal mucosa sutured with the palatal one . Clinical evaluations were conducted at regular intervals over a 3-month postoperative period, assessing wound healing, fistula recurrence, pain, facial edema, infection, and donor site morbidity.

Read the detailed description

The proposed double-layer technique achieved high success rates in closing oroantral fistulas with minimal postoperative complications, reduced facial edema, and better preservation of vestibular depth compared to conventional techniques.

A prospective clinical case series was conducted involving twelve patients with oroantral fistulas ≥5 mm in diameter. Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft rotated to cove the bony defect and sutured to the buccal periosteum as the first layer, then the buccal mucosa sutured with the palatal one . Clinical evaluations were conducted at regular intervals over a 3-month postoperative period, assessing wound healing, fistula recurrence, pain, facial edema, infection, and donor site morbidity.

This technique demonstrated reliable, tension-free closure with excellent clinical outcomes, reduced postoperative facial edema, and preserved vestibular depth, supporting its potential as an effective and safe surgical option for managing oroantral fistulas.

The purpose of the present study was explained to the patients and informed consents were obtained according to the guidelines on human research adopted by the Research Ethics Committee, Faculty of Dentistry, Tanta University.

02

Conditions studied

  • Oroantral Fistula
  • Double Layer

Keywords

  • oroantral fistula
  • double layer closure
  • buccal flap
  • palatal flap
  • rotational palatal connective tissue flap
03

In context

Lead sponsor

Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with oroantral fistula

Exclusion criteria

Exclusion Criteria:

  • patients with repeated oroantral fistula closure
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Double-Layer Closure of Oroantral Fistula Using Buccal and palatal Split-Thickness flap

    A prospective clinical case series was conducted involving twelve patients with oroantral fistulas ≥5 mm in diameter. Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft rotated to cove the bony defect and sutured to the buccal periosteum as the first layer, then the buccal mucosa sutured with the palatal one . Clinical evaluations were conducted at regular intervals over a 3-month postoperative period, assessing wound healing, fistula recurrence, pain, facial edema, infection, and donor site morbidity.

    Procedure: Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft

Interventions

  • ProcedureClosure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft

    Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft rotated to cove the bony defect and sutured to the buccal periosteum as the first layer, then the buccal mucosa sutured with the palatal one . Clinical evaluations were conducted at regular intervals over a 3-month postoperative period, assessing wound healing, fistula recurrence, pain, facial edema, infection, and donor site morbidity.

06

What researchers measure

Primary outcomes

  1. recurrence of fistula

    presence of oroantral fistula or not

    Time frame: one week -4 weeks

  2. vestibular height

    using periodontal prob

    Time frame: 1-3 months postoperatively

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2025, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 29, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Dec 10, 2025
CompletionEst.
Dec 30, 2025
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07196566
Lead sponsor
Tanta University
Responsible party
Mohamed sobhie abdelhameed (Teaching assistant in oral and maxillofacial department, faculty pf dentistry, Tanta university, Tanta University) — Principal investigator
First posted
Sep 29, 2025
Start date
Jul 28, 2025
Primary completion
Dec 10, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Sep 29, 2025

Study contacts

mohamed s abdelhameed, Asst lecturer
principal investigator · Tanta University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion